Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Earnings for Pear Therapeutics, Inc. (PEAR)
Earnings in 2022 (TTM): $-75,491,000
According to Pear Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-75,491,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Pear Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-75,491,000 | $-23,740,000 |
| 2021 | $-65,142,000 | $-20,294,000 |
| 2020 | $-97,023,000 | $-100,583,000 |
| 2019 | $-9,334,000 | $12.39 M |